Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
US-9605265-B2 · Mar 28, 2017 · US
Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
US10017582B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10017582-B2 |
| Application number | US-201615257353-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 6, 2016 |
| Priority date | Mar 16, 2009 |
| Publication date | Jul 10, 2018 |
| Grant date | Jul 10, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of reducing a cancer or malignancy, comprising administering to a subject in need thereof a composition comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for a histidyl-tRNA synthetase (HRS) splice variant polypeptide consisting of a sequence set forth in SEQ ID NO:6, 9, or 11, or a fragment of SEQ ID NO:6, 9, or 11, wherein the antibody or antigen-binding fragment thereof is at least about 90% pure. 2. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof antagonizes a non-canonical activity of the HRS splice variant polypeptide. 3. The method of claim 1 , wherein the fragment of SEQ ID NO:6, 9, or 11 consists of the WHEP domain of HRS. 4. The method of claim 1 , wherein the fragment of SEQ ID NO:9 or 11 consists of the anticodon binding domain of HRS. 5. The method of claim 1 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody. 6. The method of claim 1 , wherein the antibody is a humanized antibody. 7. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide. 8. The method of claim 1 , wherein the composition is a sterile injectable solution. 9. The method of claim 1 , wherein the composition is buffered and comprises an isotonic agent. 10. The method of claim 1 , wherein the composition is suitable for intravenous, intramuscular, subcutaneous, or intraperitoneal administration. 11. The method of claim 1 , wherein the composition comprises a surfactant. 12. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is at least about 95% pure.
Assignees
Inventors
Classifications
Immunomodulators · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Drugs for disorders of the nervous system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10017582B2 cover?
- Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
- Who is the assignee on this patent?
- Atyr Pharma Inc, Pangu Biopharma Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07K16/40. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).